{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:38:50Z","timestamp":1762843130548,"version":"build-2065373602"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T00:00:00Z","timestamp":1672012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/j.ctarc.2022.100677","type":"journal-article","created":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T02:30:28Z","timestamp":1672194628000},"page":"100677","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Paradigm change in urological, gynaecological and breast cancer management: A new practice-changing data from ASCO 2022 annual meeting"],"prefix":"10.1016","volume":"35","author":[{"given":"Meriem","family":"Andrif","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hafsa","family":"Elmarrachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5786-5134","authenticated-orcid":false,"given":"Nabil","family":"Ismaili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ctarc.2022.100677_bib0001","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.ctarc.2022.100677_bib0002","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/eurpub\/ckz216","article-title":"Cancer statistics: a comparison between World Health Organization (WHO) and Global Burden of Disease (GBD)","volume":"30","author":"Mattiuzzi","year":"2020","journal-title":"Eur. J. Public Health"},{"key":"10.1016\/j.ctarc.2022.100677_bib0003","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.canlet.2020.10.004","article-title":"APOBEC: a molecular driver in cervical cancer pathogenesis","volume":"496","author":"Revathidevi","year":"2021","journal-title":"Cancer Lett."},{"issue":"6","key":"10.1016\/j.ctarc.2022.100677_bib0004","doi-asserted-by":"crossref","first-page":"720","DOI":"10.21147\/j.issn.1000-9604.2020.06.05","article-title":"Cervical cancer: epidemiology, risk factors and screening","volume":"32","author":"Zhang","year":"2020","journal-title":"Chin. J. Cancer Res."},{"key":"10.1016\/j.ctarc.2022.100677_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.tvr.2022.200238","article-title":"Cervical cancer therapies: current challenges and future perspectives","volume":"13","author":"Burmeister","year":"2022","journal-title":"Tumour Virus Res."},{"issue":"7","key":"10.1016\/j.ctarc.2022.100677_bib0006","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1586\/era.09.58","article-title":"Cervical cancer therapy: current, future and anti-angiogensis targeted treatment","volume":"9","author":"Willmott","year":"2009","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"5","key":"10.1016\/j.ctarc.2022.100677_bib0007","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/CCO.0000000000000471","article-title":"The management of locally advanced cervical cancer","volume":"30","author":"Naga","year":"2018","journal-title":"Curr. Opin. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2022.100677_bib0008","doi-asserted-by":"crossref","first-page":"293","DOI":"10.4103\/ijmr.IJMR_4454_20","article-title":"Updates on systemic therapy for cervical cancer","volume":"154","author":"Gopu","year":"2021","journal-title":"Indian J. Med Res"},{"issue":"6","key":"10.1016\/j.ctarc.2022.100677_bib0009","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1200\/OP.21.00795","article-title":"Current management of locally advanced and metastatic cervical cancer in the United States","volume":"18","author":"Pang","year":"2022","journal-title":"JCO Oncol. Pract."},{"key":"10.1016\/j.ctarc.2022.100677_bib0010","unstructured":"Gerriets, J.P.F.V., Pembrolizumab. 2022, StatPearls, Treasure Island (FL): National Center of Biotechnology Information, National Library of Medicine."},{"issue":"20","key":"10.1016\/j.ctarc.2022.100677_bib0011","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ctarc.2022.100677_bib0012","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/0008-5472.CAN-13-2440","article-title":"An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors","volume":"74","author":"Breij","year":"2014","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.ctarc.2022.100677_bib0013","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1158\/1078-0432.CCR-19-2962","article-title":"Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer","volume":"26","author":"Hong","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.ctarc.2022.100677_bib0014","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1158\/1535-7163.MCT-14-0798","article-title":"High turnover of tissue factor enables efficient intracellular delivery of antibody\u2013drug conjugates","volume":"14","author":"De Goeij","year":"2015","journal-title":"Mol. Cancer Ther."},{"issue":"18","key":"10.1016\/j.ctarc.2022.100677_bib0015","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s40265-021-01633-8","article-title":"Tisotumab vedotin: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ctarc.2022.100677_bib0016","series-title":"Comprehensive Pharmacology","first-page":"211","article-title":"6.12 - bladder cancer","author":"Almousa","year":"2022"},{"issue":"5","key":"10.1016\/j.ctarc.2022.100677_bib0017","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1358\/dot.2022.58.5.3400745","article-title":"Tisotumab vedotin for the treatment of cervical carcinoma","volume":"58","author":"Song","year":"2022","journal-title":"Drugs Today (Barc)"},{"issue":"5","key":"10.1016\/j.ctarc.2022.100677_bib0018","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol."},{"issue":"15_suppl","key":"10.1016\/j.ctarc.2022.100677_bib0019","doi-asserted-by":"crossref","first-page":"TPS6095","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS6095","article-title":"Phase Ib\/II trial of tisotumab vedotin (TV) \u00b1 bevacizumab (BEV), pembrolizumab (PEM), or carboplatin (CBP) in recurrent or metastatic cervical cancer (innovaTV 205\/ENGOT-cx8\/GOG-3024)","volume":"38","author":"Vergote","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2022.100677_bib0020","article-title":"Global patterns and trends in ovarian cancer incidence: age, period and birth cohort analysis","volume":"19","author":"Zhang","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctarc.2022.100677_bib0021","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2147\/IJWH.S197604","article-title":"Ovarian cancer in the world: epidemiology and risk factors","volume":"11","author":"Momenimovahed","year":"2019","journal-title":"Int. J. Womens Health"},{"issue":"2","key":"10.1016\/j.ctarc.2022.100677_bib0022","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.soncn.2019.02.001","article-title":"Ovarian cancer: an integrated review","volume":"35","author":"Stewart","year":"2019","journal-title":"Semin Oncol. Nurs."},{"issue":"4","key":"10.1016\/j.ctarc.2022.100677_bib0023","first-page":"284","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA: A Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.ctarc.2022.100677_bib0024","doi-asserted-by":"crossref","first-page":"47","DOI":"10.21037\/cco-20-34","article-title":"Epidemiology of ovarian cancer","volume":"9","author":"Gaona-Luviano","year":"2020","journal-title":"Chinese Clin. Oncol."},{"key":"10.1016\/j.ctarc.2022.100677_bib0025","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.dnarep.2018.08.021","article-title":"Mechanisms of PARP inhibitor sensitivity and resistance","volume":"71","author":"D'Andrea","year":"2018","journal-title":"DNA Repair"},{"issue":"6330","key":"10.1016\/j.ctarc.2022.100677_bib0026","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"issue":"5-6","key":"10.1016\/j.ctarc.2022.100677_bib0027","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1101\/gad.334516.119","article-title":"PARP and PARG inhibitors in cancer treatment","volume":"34","author":"Slade","year":"2020","journal-title":"Genes Dev."},{"issue":"26","key":"10.1016\/j.ctarc.2022.100677_bib0028","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.ctarc.2022.100677_bib0029","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.ctarc.2022.100677_bib0030","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1136\/ijgc-2021-002933","article-title":"ATHENA (GOG-3020\/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA\u2013MONO) and rucaparib in combination with nivolumab (ATHENA\u2013COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian c","volume":"31","author":"Monk","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ctarc.2022.100677_bib0031","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.22.01003","article-title":"A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA\u2013MONO\/GOG-3020\/ENGOT-ov45)","author":"Monk","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.ctarc.2022.100677_bib0032","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1200\/JCO.2022.40.16_suppl.5519","article-title":"Maintenance olaparib in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by somatic (s) or germline (g) BRCA and other homologous recombination repair (HRR) gene mutation status: overall survival (OS) results from the ORZORA study","volume":"40","author":"Pignata","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.ctarc.2022.100677_bib0033","doi-asserted-by":"crossref","first-page":"5551","DOI":"10.1200\/JCO.2022.40.16_suppl.5551","article-title":"Efficacy of niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer in phase 3 PRIME study: a subgroup analysis by response to first-line platinum-based chemotherapy","volume":"40","author":"Yin","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.ctarc.2022.100677_bib0034","doi-asserted-by":"crossref","first-page":"5553","DOI":"10.1200\/JCO.2022.40.16_suppl.5553","article-title":"Identification of patients with ovarian cancer who are experiencing the highest benefit from bevacizumab in first-line setting based on their tumor intrinsic chemosensitivity (KELIM): GOG-0218 validation study","volume":"40","author":"You","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.ctarc.2022.100677_bib0035","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.19.01009","article-title":"Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer","volume":"37","author":"Tewari","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2022.100677_bib0036","doi-asserted-by":"crossref","DOI":"10.3390\/molecules22020250","article-title":"Emerging cytotoxic alkaloids in the battle against cancer: overview of molecular mechanisms","volume":"22","author":"Habli","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.ctarc.2022.100677_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172472","article-title":"Alkaloids for cancer prevention and therapy: current progress and future perspectives","volume":"858","author":"Mondal","year":"2019","journal-title":"Eur. J. Pharmacol."},{"issue":"15","key":"10.1016\/j.ctarc.2022.100677_bib0038","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.2165\/00003495-200767150-00009","article-title":"Trabectedin: a review of its use in the management of soft tissue sarcoma and ovarian cancer","volume":"67","author":"Carter","year":"2007","journal-title":"Drugs"},{"issue":"17_suppl","key":"10.1016\/j.ctarc.2022.100677_bib0039","doi-asserted-by":"crossref","first-page":"LBA5504","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA5504","article-title":"Randomized phase III trial on trabectedin (ET-743) single agent versus clinician's choice chemotherapy in recurrent ovarian, primary peritoneal, or fallopian tube cancers of BRCA-mutated or BRCAness phenotype patients (MITO23)","volume":"40","author":"Scambia","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2022.100677_bib0040","article-title":"Monoclonal antibodies in cancer therapy","volume":"9","author":"Zahavi","year":"2020","journal-title":"Antibodies (Basel)"},{"issue":"17_suppl","key":"10.1016\/j.ctarc.2022.100677_bib0041","doi-asserted-by":"crossref","first-page":"LBA5503","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA5503","article-title":"Overall survival data from a 3-arm, randomized, open-label, phase 2 study of relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer","volume":"40","author":"Colombo","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2022.100677_bib0042","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41416-020-01161-4","article-title":"The lingering mysteries of metastatic recurrence in breast cancer","volume":"124","author":"Riggio","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.ctarc.2022.100677_bib0043","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40291-021-00525-7","article-title":"Luminal breast cancer: risk of recurrence and tumor-associated immune suppression","volume":"25","author":"Pellegrino","year":"2021","journal-title":"Mol. Diagn. Therapy"},{"issue":"2","key":"10.1016\/j.ctarc.2022.100677_bib0044","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer \u2014 expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2022.100677_bib0045","article-title":"Progress and challenges of immunotherapy in triple-negative breast cancer","volume":"1876","author":"Zhu","year":"2021","journal-title":"Biochim. Biophys. Acta (BBA) - Rev. Cancer"},{"issue":"6","key":"10.1016\/j.ctarc.2022.100677_bib0046","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/13543784.2022.2008354","article-title":"Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond","volume":"31","author":"Rizzo","year":"2022","journal-title":"Expert Opin. Investig. Drugs,"},{"issue":"6","key":"10.1016\/j.ctarc.2022.100677_bib0047","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1080\/13543784.2022.2009456","article-title":"Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects","volume":"31","author":"Rizzo","year":"2022","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"1","key":"10.1016\/j.ctarc.2022.100677_bib0048","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ctarc.2022.100677_bib0049","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ctarc.2022.100677_bib0050","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1158\/1078-0432.CCR-20-3646","article-title":"Randomized phase II trial of anthracycline-free and anthracycline-containing neoadjuvant carboplatin chemotherapy regimens in stage I\u2013III triple-negative breast cancer (NeoSTOP)","volume":"27","author":"Sharma","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"16_suppl","key":"10.1016\/j.ctarc.2022.100677_bib0051","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1200\/JCO.2022.40.16_suppl.513","article-title":"Clinical and biomarker results of neoadjuvant phase II study of pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer (TNBC) (NeoPACT)","volume":"40","author":"Sharma","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"4_Supplement","key":"10.1016\/j.ctarc.2022.100677_bib0052","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS20-OT-03-06","article-title":"Abstract OT-03-06: phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer (NeoSTAR)","volume":"81","author":"Spring","year":"2021","journal-title":"Cancer Res."},{"issue":"16_suppl","key":"10.1016\/j.ctarc.2022.100677_bib0053","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1200\/JCO.2022.40.16_suppl.512","article-title":"Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: results from the NeoSTAR trial","volume":"40","author":"Spring","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"17_suppl","key":"10.1016\/j.ctarc.2022.100677_bib0054","doi-asserted-by":"crossref","first-page":"LBA1001","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA1001","article-title":"Primary results from TROPiCS-02: a randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician's choice (TPC) in patients (Pts) with hormone receptor\u2013positive\/HER2-negative (HR+\/HER2-) advanced breast cancer","volume":"40","author":"Rugo","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.ctarc.2022.100677_bib0055","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1200\/JCO.2022.40.16_suppl.1002","article-title":"Results from the phase 1\/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC)","volume":"40","author":"Krop","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"17_suppl","key":"10.1016\/j.ctarc.2022.100677_bib0056","doi-asserted-by":"crossref","first-page":"LBA1003","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA1003","article-title":"Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor\u2013positive\/human epidermal growth factor receptor 2\u2013negative advanced breast cancer (ER+\/HER2\u2212 ABC): analyses","volume":"40","author":"Finn","year":"2022","journal-title":"J. Clin. Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ctarc.2022.100677_bib0057","doi-asserted-by":"crossref","first-page":"TPS1112","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS1112","article-title":"A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4\/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer","volume":"35","author":"Kalinsky","year":"2017","journal-title":"J. Clin. Oncol"},{"issue":"17_suppl","key":"10.1016\/j.ctarc.2022.100677_bib0058","doi-asserted-by":"crossref","first-page":"LBA1004","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA1004","article-title":"A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4\/6 inhibition (CDK 4\/6i) in patients (pts) with unresectable or hormone receptor\u2013positive (HR+)","volume":"40","author":"Kalinsky","year":"2022","journal-title":"J. Clin. Oncol"},{"issue":"16_suppl","key":"10.1016\/j.ctarc.2022.100677_bib0059","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1200\/JCO.2022.40.16_suppl.500","article-title":"Final results from a phase III randomized clinical trial of adjuvant endocrine therapy \u00b1 chemotherapy in women \u2265 70 years old with ER+ HER2- breast cancer and a high genomic grade index: the Unicancer ASTER 70s trial","volume":"40","author":"Brain","year":"2022","journal-title":"J. Clin. Oncol"},{"issue":"1","key":"10.1016\/j.ctarc.2022.100677_bib0060","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12935-021-01813-2","article-title":"Prognostic significance of pretreatment controlling nutritional status score in urological cancers: a systematic review and meta-analysis","volume":"21","author":"Niu","year":"2021","journal-title":"Cancer Cell Int."},{"issue":"1","key":"10.1016\/j.ctarc.2022.100677_bib0061","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41585-020-00389-2","article-title":"Patient-derived tumour models for personalized therapeutics in urological cancers","volume":"18","author":"van de Merbel","year":"2021","journal-title":"Nat. Rev.Urol."},{"issue":"7","key":"10.1016\/j.ctarc.2022.100677_bib0062","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.3390\/cancers13071529","article-title":"Urinary extracellular vesicles as potential biomarkers for urologic cancers: an overview of current methods and advances","volume":"13","author":"Louren\u00e7o","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ctarc.2022.100677_bib0063","doi-asserted-by":"crossref","DOI":"10.1016\/j.envres.2020.110485","article-title":"Endocrine-disrupting effects of bisphenols on urological cancers","volume":"195","author":"Pellerin","year":"2021","journal-title":"Environ. Res."},{"issue":"4","key":"10.1016\/j.ctarc.2022.100677_bib0064","first-page":"313","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"70","year":"2020","journal-title":"CA: Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.ctarc.2022.100677_bib0065","doi-asserted-by":"crossref","first-page":"21701","DOI":"10.1038\/s41598-021-01103-x","article-title":"Sugary drink consumption and risk of kidney and bladder cancer in Japanese adults","volume":"11","author":"Leung","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ctarc.2022.100677_bib0066","first-page":"60","article-title":"Global, regional, and national burden of kidney, bladder, and prostate cancers and their attributable risk factors, 1990-2019","volume":"8","author":"Zi","year":"2021","journal-title":"Mil. Med. Res."},{"issue":"10","key":"10.1016\/j.ctarc.2022.100677_bib0067","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1007\/s00345-022-04110-3","article-title":"Improving survival in metastatic renal cell carcinoma (mRCC) patients: do elderly patients benefit from expanded targeted therapeutic options?","volume":"40","author":"Eggers","year":"2022","journal-title":"World J. Urol."},{"issue":"4","key":"10.1016\/j.ctarc.2022.100677_bib0068","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/JCMA.0000000000000701","article-title":"Management of metastatic renal cell carcinoma following prior vascular endothelial growth factor\u2013targeted therapy: a real-world retrospective study from Taiwan","volume":"85","author":"Chung","year":"2022","journal-title":"J. Chinese Med. Assoc."},{"issue":"10","key":"10.1016\/j.ctarc.2022.100677_bib0069","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1007\/s00345-022-04015-1","article-title":"Systemic therapy in metastatic renal cell carcinoma (mRCC): an evidence-based recommendation of the German interdisciplinary RCC guidelines group","volume":"40","author":"Gr\u00fcnwald","year":"2022","journal-title":"World J. Urol."},{"key":"10.1016\/j.ctarc.2022.100677_bib0070","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920907504","article-title":"Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma","volume":"12","author":"Rassy","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"10","key":"10.1016\/j.ctarc.2022.100677_bib0071","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1080\/14740338.2020.1811226","article-title":"Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis","volume":"19","author":"Massari","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"issue":"1","key":"10.1016\/j.ctarc.2022.100677_bib0072","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11523-021-00861-y","article-title":"Concomitant proton pump inhibitors and outcome of patients treated with nivolumab alone or plus ipilimumab for advanced renal cell carcinoma","volume":"17","author":"Mollica","year":"2022","journal-title":"Target Oncol."},{"issue":"17_suppl","key":"10.1016\/j.ctarc.2022.100677_bib0073","doi-asserted-by":"crossref","first-page":"LBA4500","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA4500","article-title":"EVEREST: everolimus for renal cancer ensuing surgical therapy\u2014a phase III study (SWOG S0931, NCT01120249)","volume":"40","author":"Ryan","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"6_suppl","key":"10.1016\/j.ctarc.2022.100677_bib0074","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1200\/JCO.2022.40.6_suppl.290","article-title":"Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: results from 30-month follow-up of KEYNOTE-564","volume":"40","author":"Choueiri","year":"2022","journal-title":"J. Clin. Oncol"},{"issue":"6_suppl","key":"10.1016\/j.ctarc.2022.100677_bib0075","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1200\/JCO.2022.40.6_suppl.350","article-title":"Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in checkmate 9ER: nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma","volume":"40","author":"Powles","year":"2022","journal-title":"J. Clin. Oncol"},{"issue":"14","key":"10.1016\/j.ctarc.2022.100677_bib0076","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"15_suppl","key":"10.1016\/j.ctarc.2022.100677_bib0077","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1200\/JCO.2021.39.15_suppl.4500","article-title":"Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): results from 42-month follow-up of KEYNOTE-426","volume":"39","author":"Rini","year":"2021","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.ctarc.2022.100677_bib0078","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2022.06.009","article-title":"Health-related quality of life analysis from KEYNOTE-426: pembrolizumab plus axitinib versus sunitinib for advanced renal cell carcinoma","author":"Bedke","year":"2022","journal-title":"Eur. Urol."},{"issue":"16_suppl","key":"10.1016\/j.ctarc.2022.100677_bib0079","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1200\/JCO.2022.40.16_suppl.4517","article-title":"Avelumab as the basis of neoadjuvant regimen in platinum-eligible and -ineligible patients with nonmetastatic muscle-invasive bladder cancer: AURA (Oncodistinct-004) trial","volume":"40","author":"Martinez Chanza","year":"2022","journal-title":"J. Clin. Oncol"},{"issue":"6_suppl","key":"10.1016\/j.ctarc.2022.100677_bib0080","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1200\/JCO.2022.40.6_suppl.487","article-title":"Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): long-term follow-up results from the JAVELIN bladder 100 trial","volume":"40","author":"Powles","year":"2022","journal-title":"J. Clin. Oncol"},{"issue":"16_suppl","key":"10.1016\/j.ctarc.2022.100677_bib0081","doi-asserted-by":"crossref","first-page":"4516","DOI":"10.1200\/JCO.2022.40.16_suppl.4516","article-title":"Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma","volume":"40","author":"Rosenberg","year":"2022","journal-title":"J. Clin. Oncol"},{"issue":"12","key":"10.1016\/j.ctarc.2022.100677_bib0082","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"16_suppl","key":"10.1016\/j.ctarc.2022.100677_bib0083","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1200\/JCO.2022.40.16_suppl.5005","article-title":"A phase 3 trial of SHR3680 versus bicalutamide in combination with androgen deprivation therapy (ADT) in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC)","volume":"40","author":"Ye","year":"2022","journal-title":"J. Clin. Oncol"},{"issue":"16_suppl","key":"10.1016\/j.ctarc.2022.100677_bib0084","doi-asserted-by":"crossref","first-page":"5081","DOI":"10.1200\/JCO.2022.40.16_suppl.5081","article-title":"Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC): an analysis from the ECOG-ACRIN 3805 (CHAARTED) trial","volume":"40","author":"Tripathi","year":"2022","journal-title":"J. Clin. Oncol"},{"issue":"16_suppl","key":"10.1016\/j.ctarc.2022.100677_bib0085","doi-asserted-by":"crossref","first-page":"5070","DOI":"10.1200\/JCO.2022.40.16_suppl.5070","article-title":"Defining more precisely the effects of docetaxel plus ADT for men with mHSPC: meta-analysis of individual participant data from randomized trials","volume":"40","author":"Vale","year":"2022","journal-title":"J. Clin. Oncol"},{"issue":"10336","key":"10.1016\/j.ctarc.2022.100677_bib0086","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u2009\u00d7\u20092 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"issue":"6_suppl","key":"10.1016\/j.ctarc.2022.100677_bib0087","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.2022.40.6_suppl.013","article-title":"Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial","volume":"40","author":"Smith","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.ctarc.2022.100677_bib0088","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"6_suppl","key":"10.1016\/j.ctarc.2022.100677_bib0089","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.2022.40.6_suppl.011","article-title":"PROpel: phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"40","author":"Saad","year":"2022","journal-title":"J. Clin. Oncol"},{"issue":"9","key":"10.1016\/j.ctarc.2022.100677_bib0090","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and olaparib for metastatic castration-resistant prostate cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evid."},{"issue":"16_suppl","key":"10.1016\/j.ctarc.2022.100677_bib0091","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1200\/JCO.2022.40.16_suppl.5018","article-title":"BRCAAWAY: a randomized phase 2 trial of abiraterone, olaparib, or abiraterone\u00a0+\u00a0olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects","volume":"40","author":"Hussain","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"6_suppl","key":"10.1016\/j.ctarc.2022.100677_bib0092","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/JCO.2022.40.6_suppl.117","article-title":"Phase 2 randomized trial of ModraDoc006\/r, oral docetaxel plus ritonavir, versus intravenous docetaxel in metastatic castration resistant prostate cancer (mCRPC)","volume":"40","author":"Vaishampayan","year":"2022","journal-title":"J. Clin. Oncol."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246829422200168X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246829422200168X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:35:28Z","timestamp":1762842928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S246829422200168X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":92,"alternative-id":["S246829422200168X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2022.100677","relation":{},"ISSN":["2468-2942"],"issn-type":[{"type":"print","value":"2468-2942"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Paradigm change in urological, gynaecological and breast cancer management: A new practice-changing data from ASCO 2022 annual meeting","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2022.100677","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100677"}}